 |
|
Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation
A Systematic Review of Randomized Controlled Trials
Carmelo Lafuente-Lafuente, MD;
Stéphane Mouly, MD, PhD;
Miguel Angel Longás-Tejero, MD, PhD;
Isabelle Mahé, MD, PhD;
Jean-François Bergmann, MD
Arch Intern Med. 2006;166:719-728.
Background A variety of antiarrhythmic drugs have been used to prevent recurrence of atrial fibrillation after conversion to sinus rhythm. We performed a systematic review to determine the effect of long-term treatment with those drugs on death, embolisms, adverse effects, and atrial fibrillation recurrence.
Methods We searched MEDLINE, EMBASE, the Cochrane Library (all up to May 2005), and the reference lists of retrieved articles. We included randomized controlled trials that compared any antiarrhythmic against control (placebo or no treatment) or another antiarrhythmic, for more than 6 months. Postoperative atrial fibrillation was excluded. Two evaluators independently reviewed the retrieved studies and extracted all data. Disagreements were resolved by discussion. All results were calculated at 1 year of follow-up.
Results Forty-four trials were included, with a total of 11 322 patients. Several class IA (disopyramide phosphate, quinidine sulfate), class IC (flecainide acetate, propafenone hydrochloride), and class III (amiodarone, dofetilide, sotalol hydrochloride) drugs significantly reduced recurrence of atrial fibrillation (number needed to treat, 2-9), but all increased withdrawals due to adverse effects (number needed to harm [NNH], 9-27) and all but amiodarone and propafenone increased proarrhythmia (NNH, 17-119). Class IA drugs, pooled, were associated with increased mortality compared with controls (Peto odds ratio, 2.39; 95% confidence interval, 1.03-5.59; P = .04; NNH, 109). No other antiarrhythmic showed a significant effect on mortality compared with controls. We could not analyze other outcomes because data were lacking.
Conclusion Class IA, IC, and III drugs are effective in maintaining sinus rhythm but increase adverse effects, and class IA drugs may increase mortality.
Author Affiliations: Service de Médecine Interne A, Hôpital Lariboisière, Paris, France (Drs Lafuente-Lafuente, Mouly, Mahé, and Bergmann); and Servicio de Cardiología, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (Dr Longás-Tejero).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTERS
Ignoring Study Design Heterogeneity in Meta-analyses
J. Jaime Caro, James G. Xenakis, and Krista F. Huybrechts
Arch Intern Med. 2006;166(18):2046.
EXTRACT
| FULL TEXT
Ignoring Study Design Heterogeneity in Meta-analyses—Reply
Carmelo Lafuente-Lafuente, Stephane Mouly, Isabelle Mahe, and Jean-François Bergmann
Arch Intern Med. 2006;166(18):2046-2047.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Kirchhof et al.
Europace 2009;11:860-885.
FULL TEXT
How safe is the antiarrhythmic drug therapy in atrial fibrillation?
Krishnamoorthy and Lip
Europace 2009;11:837-839.
FULL TEXT
Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Crandall et al.
Mayo Clin Proc. 2009;84:643-662.
ABSTRACT
| FULL TEXT
Antiarrhythmic Drug-Induced Internalization of the Atrial-Specific K+ Channel Kv1.5
Schumacher et al.
Circ. Res. 2009;104:1390-1398.
ABSTRACT
| FULL TEXT
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'
Kirchhof et al.
Eur Heart J 2009;0:ehp235v1-ehp235.
ABSTRACT
| FULL TEXT
Valsartan for Prevention of Recurrent Atrial Fibrillation
The GISSI-AF Investigators
NEJM 2009;360:1606-1617.
ABSTRACT
| FULL TEXT
Antifibrillatory Agents and Potassium Channels in the Atria: Pore Block versus Channel Trafficking
McEwen and Martens
Mol. Interv. 2009;9:79-86.
ABSTRACT
| FULL TEXT
Atrial fibrillation ablation: beyond electro-mechanical matters
Martignani et al.
Eur Heart J 2008;29:2818-2819.
FULL TEXT
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
Savelieva and Camm
Europace 2008;10:647-665.
ABSTRACT
| FULL TEXT
An irregularly irregular inheritance.
London
J Am Coll Cardiol 2008;51:1090-1091.
FULL TEXT
Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode
Cosio et al.
Europace 2008;10:21-27.
ABSTRACT
| FULL TEXT
Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
Vassallo and Trohman
JAMA 2007;298:1312-1322.
ABSTRACT
| FULL TEXT
Amiodarone-Induced Thyrotoxicosis: Clinical Course and Predictors of Outcome
Conen et al.
J Am Coll Cardiol 2007;49:2350-2355.
ABSTRACT
| FULL TEXT
A clinical and health-economic evaluation of pulmonary vein encircling ablation compared with antiarrhythmic drug treatment in patients with persistent atrial fibrillation (Catheter Ablation for the Cure of Atrial Fibrillation-2 study)
Bertaglia et al.
Europace 2007;9:182-185.
ABSTRACT
| FULL TEXT
Ignoring Study Design Heterogeneity in Meta-analyses.
Caro et al.
Arch Intern Med 2006;166:2046-2046.
FULL TEXT
Ignoring Study Design Heterogeneity in Meta-analyses--Reply
Lafuente-Lafuente et al.
Arch Intern Med 2006;166:2046-2047.
FULL TEXT
Antiarrhythmic Drugs for Managing AFib: A Meta-Analysis
Journal Watch Cardiology 2006;2006:2-2.
FULL TEXT
|
